← Back

Suzhou Medsys Tech Co Ltd

Suzhou MedicalSystem Technology Co., Ltd. provides solutions in clinical informatics and digital hospital field in China. It offers DoCare anesthesia clinical information system that focuses on serving the perioperative clinical work; and provides streamlined, informational, automatic, and intelligent integrated management platform for clinical business. The company also provides DoCare intensive auxiliary diagnosis clinical information system that mines and scientifically analyzes for ICU patients' treatment data with medical information, such as patients' treatment information, inspection information, nursing information, and doctor's advice data. In addition, it offers DoCare operative medical behavior management system that establishes the intelligent management system for the operation resources and personnel behavior; and DoCare emergency clinical information system for management of emergency clinical, including pre-hospital first aid, pre-examination and triage, emergency rescue, emergency under observation, emergency operating room, emergency ICU, and patient outcome. Further, the company provides DoCare pre-hospital first aid clinical information system that provides a unified service platform, which has digital information for emergency command center, emergency doctors, emergency nurses, visiting medical personnel, and patients. Additionally, it offers smart OT, ICU, and emergency solutions; and smart specialty solutions, such as laminar airflow room, clinical pathway, and mobile nursing information systems, as well as central sterile supply department management systems. The company was founded in 2005 and is based in Suzhou, China.

Price · split & dividend adjusted
News & notes moving 603990.CG
603990.CG▼

Maidi Technology's 2026 interim net profit was 6.6332 million yuan, down 76.58% year-on-year

Maidi Technology released its 2026 interim report. The company's total operating revenue was 123 million yuan, down 8.90% year-on-year. Net profit attributable to the parent company was 6.6332 million yuan, down 76.58% year-on-year. Net cash flow from operating activities was negative 344,900 yuan, but increased by 4.4273 million yuan compared with the same period last year, achieving growth for two consecutive years. The company's asset-liability ratio was 29.78%, gross margin was 60.14%, ROE was 0.79%, and diluted earnings per share was 0.02 yuan. The number of shareholders was 23,800, and the top ten shareholders held 28.60% of the total share capital.
603990.CG ▼
Jiemian·11hRead more ▾
Artificial Intelligence▲

MediTech joins hands with Sugon to build a closed loop for AI healthcare

MediTech and Sugon have signed a long-term strategic cooperation agreement to jointly promote the localization of AI healthcare and build a closed loop covering data, models, computing power, scenarios, and hardware. The two sides will collaborate on adapting large models for healthcare and elderly care, system integration, and product development, creating standardized and replicable integrated solutions that merge medical expertise with intelligence. MediTech has been deeply engaged in healthcare informatization for over two decades, serving more than 2,400 medical institutions nationwide across core clinical scenarios such as emergency, anesthesia, operating rooms, and ICUs, and has accumulated a high-quality clinical data resource pool. This cooperation combines Sugon's domestically developed computing power foundation with MediTech's clinical scenarios and data barriers, forming a full-stack delivery capability from underlying computing power to upper-layer applications, with plans to expand into diverse businesses such as smart education and smart cities.
603990.CG ▲603019.CG ▲
Artificial Intelligence ▲Cloud & Digital Infrastructure
Jiemian·17dRead more ▾
603990.CG▼

Medi-Tech expects first-half 2026 net profit attributable to parent to fall 69.99%–77.05% year-on-year

Medi-Tech disclosed an earnings forecast, expecting net profit attributable to the parent for the first half of 2026 to be between 6.5 million yuan and 8.5 million yuan, a year-on-year decline of 69.99% to 77.05%. Net profit after deducting non-recurring items is expected to be between 5.5 million yuan and 7.5 million yuan, a year-on-year increase of 52.57% to 108.05%. The company stated that the decline in net profit attributable to the parent was mainly due to the completion of a major asset sale in the first half of 2025, which generated a large investment gain from the disposal of a photovoltaic subsidiary, creating a high base. At the same time, the company continued to optimize its business structure and promote refined management, leading to a year-on-year increase in net profit after deducting non-recurring items.
603990.CG ▼
中国证券报·44dRead more ▾
© 2026 MarketDXAsset